The goal of this implementation science study is to learn about the experience of receiving and providing cabotegravir + rilpivirine long-acting (CAB+RPV LA) injections as treatment for human immunodeficiency virus (HIV) for people who live a significant distance from an HIV provider. The main questions it aims to answer are: * Is CAB+RPV LA feasible and acceptable to patients and staff? * What barriers and supports exist and have the most impact on receiving and providing CAB+RPV LA? * How does CAB+RPV LA affect HIV stigma, treatment satisfaction, medication adherence and viral suppression? People living with HIV who reside outside of the Omaha, Nebraska metro area and are starting CAB+RPV LA as part of regular medical care for HIV will be invited to participate in this study which involves completing questionnaires and an interview over 15 months. Clinic staff who are involved in providing HIV care and CAB+RPV LA will also provide input through questionnaires and an interview.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Patient participants determination of acceptability of CAB+RPV LA implementation
Timeframe: 15 months (baseline, month 7 & month 15)
Patient participants determination of feasibility of CAB+RPV LA implementation
Timeframe: 15 months (baseline, month 7 & month 15)
Staff participants determination of the acceptability of CAB+RPV LA implementation
Timeframe: 15 months (baseline, month 7 & month 15)
Staff participants determination of the feasibility of CAB+RPV LA implementation
Timeframe: 15 months (baseline, month 7 & month 15)